Core Viewpoint - Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma for the development of YP05002, a small molecule GLP-1 receptor agonist aimed at chronic weight management, currently in Phase 1 development [1][2] Group 1: Collaboration and Financial Terms - Under the agreement, YaoPharma will complete the ongoing Phase 1 clinical trial for YP05002 and grant Pfizer an exclusive license for further development, manufacturing, and commercialization worldwide [2] - YaoPharma will receive an upfront payment of $150 million and is eligible for milestone payments up to $1.935 billion, along with tiered royalties on sales if the drug is approved [2] Group 2: Strategic Importance and Future Plans - Pfizer views cardiometabolic research as a strategic priority that could drive significant growth for the company [2] - Pfizer plans to conduct combination studies of YP05002 with its GIPR antagonist PF-07976016, which is currently in Phase 2 development, as well as with other small molecules in its pipeline [3]